AAAAAA

   
Results: 1-14 |
Results: 14
CMB-401 - A CYTOTOXIC IMMUNOCONJUGATE FOR TARGETED THERAPY OF EPITHELIAL OVARIAN-CANCER
Authors: BROADHEAD TJ GILLESPIE AM COLEMAN RE OWEN J SKELTON L STEPHENS S FARNSWORTH A SOPWITH M CHAN SY
Citation: Tj. Broadhead et al., CMB-401 - A CYTOTOXIC IMMUNOCONJUGATE FOR TARGETED THERAPY OF EPITHELIAL OVARIAN-CANCER, Annals of oncology, 9, 1998, pp. 320-320
BIODISTRIBUTION OF IN-111-LABELED ENGINEERED HUMAN-ANTIBODY CTM01 (HCTM01) IN OVARIAN-CANCER PATIENTS - INFLUENCE OF PRIOR ADMINISTRATION OF UNLABELED HCTM01
Authors: PRINSSEN HM MOLTHOFF CFM VERHEIJEN RHM BROADHEAD TJ KENEMANS P ROOS JC DAVIES Q VANHOF AC FRIER M DENHOLLANDER W WILHELM AJ BAKER TS SOPWITH M SYMONDS EM PERKINS AC
Citation: Hm. Prinssen et al., BIODISTRIBUTION OF IN-111-LABELED ENGINEERED HUMAN-ANTIBODY CTM01 (HCTM01) IN OVARIAN-CANCER PATIENTS - INFLUENCE OF PRIOR ADMINISTRATION OF UNLABELED HCTM01, Cancer immunology and immunotherapy, 47(1), 1998, pp. 39-46
PHASE-I STUDY OF ASCENDING DOSES OF THE CYTOTOXIC IMMUNOCONJUGATE CMB-401 (HCTMO1-CALICHEAMICIN) IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER
Authors: GILLESPIE AM BROADHEAD TJ CHAN SY OWEN J FARNSWORTH AP SOPWITH M COLEMAN RE
Citation: Am. Gillespie et al., PHASE-I STUDY OF ASCENDING DOSES OF THE CYTOTOXIC IMMUNOCONJUGATE CMB-401 (HCTMO1-CALICHEAMICIN) IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER, British Journal of Cancer, 78, 1998, pp. 60-60
CMB-401 - A NEW AGENT FOR IMMUNOTHERAPY OF EPITHELIAL OVARIAN-CANCER - IMMUNE-RESPONSE AND PHARMACOKINETICS
Authors: BROADHEAD TJ GILLESPIE AM COLEMAN RE OWEN J SKELTON L STEPHENS S FARNSWORTH A SOPWITH M CHAN SY
Citation: Tj. Broadhead et al., CMB-401 - A NEW AGENT FOR IMMUNOTHERAPY OF EPITHELIAL OVARIAN-CANCER - IMMUNE-RESPONSE AND PHARMACOKINETICS, British Journal of Cancer, 78, 1998, pp. 63-63
RANDOMIZED CONTROLLED TRIAL OF CDP571 ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA IN CROHNS-DISEASE
Authors: STACK WA MANN SD ROY AJ HEATH P SOPWITH M FREEMAN J HOLMES G LONG R FORBES A KAMM MA HAWKEY CJ
Citation: Wa. Stack et al., RANDOMIZED CONTROLLED TRIAL OF CDP571 ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA IN CROHNS-DISEASE, Lancet, 349(9051), 1997, pp. 521-524
THE EFFECTS OF CDP571, AN ENGINEERED HUMAN IGG(4) ANTI-TNF-ALPHA ANTIBODY IN CROHNS-DISEASE
Authors: STACK W MANN S ROY A HEATH P SOPWITH M FREEMAN J HOLMES G LONG R FORBES A KAMM M HAWKEY C
Citation: W. Stack et al., THE EFFECTS OF CDP571, AN ENGINEERED HUMAN IGG(4) ANTI-TNF-ALPHA ANTIBODY IN CROHNS-DISEASE, Gastroenterology, 110(4), 1996, pp. 1018-1018
EFFECTS OF AN ENGINEERED HUMAN ANTI-TNF-ALPHA ANTIBODY (CDP571) ON INSULIN SENSITIVITY AND GLYCEMIC CONTROL IN PATIENTS WITH NIDDM
Authors: OFEI F HUREL S NEWKIRK J SOPWITH M TAYLOR R
Citation: F. Ofei et al., EFFECTS OF AN ENGINEERED HUMAN ANTI-TNF-ALPHA ANTIBODY (CDP571) ON INSULIN SENSITIVITY AND GLYCEMIC CONTROL IN PATIENTS WITH NIDDM, Diabetes, 45(7), 1996, pp. 881-885
BIODISTRIBUTION OF (111)INDIUM-LABELED ENGINEERED HUMAN-ANTIBODY CTMO1 IN OVARIAN-CANCER PATIENTS - INFLUENCE OF PROTEIN DOSE
Authors: VANHOF AC MOLTHOFF CFM DAVIES Q PERKINS AC VERHEIJEN RHM KENEMANS P DENHOLLANDER W WILHELM AJ BAKER TS SOPWITH M FRIER M SYMONDS EM ROOS JC
Citation: Ac. Vanhof et al., BIODISTRIBUTION OF (111)INDIUM-LABELED ENGINEERED HUMAN-ANTIBODY CTMO1 IN OVARIAN-CANCER PATIENTS - INFLUENCE OF PROTEIN DOSE, Cancer research, 56(22), 1996, pp. 5179-5185
CDP571, A HUMANIZED ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA - SAFETY, PHARMACOKINETICS, IMMUNE-RESPONSE, AND INFLUENCE OF THE ANTIBODY ON CYTOKINE CONCENTRATIONS IN PATIENTS WITH SEPTIC SHOCK
Authors: DHAINAUT JFA VINCENT JL RICHARD C LEJEUNE P MARTIN C FIEROBE L STEPHENS S NEY UM SOPWITH M MERCAT A EDOUARD A FRIEDMAN G MARIN N SCHLEMMER B LEPAPE A NOVAK C
Citation: Jfa. Dhainaut et al., CDP571, A HUMANIZED ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA - SAFETY, PHARMACOKINETICS, IMMUNE-RESPONSE, AND INFLUENCE OF THE ANTIBODY ON CYTOKINE CONCENTRATIONS IN PATIENTS WITH SEPTIC SHOCK, Critical care medicine, 23(9), 1995, pp. 1461-1469
COMPREHENSIVE PHARMACOKINETICS OF A HUMANIZED ANTIBODY AND ANALYSIS OF RESIDUAL ANTIIDIOTYPIC RESPONSES
Authors: STEPHENS S EMTAGE S VETTERLEIN O CHAPLIN L BEBBINGTON C NESBITT A SOPWITH M ATHWAL D NOVAK C BODMER M
Citation: S. Stephens et al., COMPREHENSIVE PHARMACOKINETICS OF A HUMANIZED ANTIBODY AND ANALYSIS OF RESIDUAL ANTIIDIOTYPIC RESPONSES, Immunology, 85(4), 1995, pp. 668-674
REPEATED DOSES OF 10 MG KG OF AN ENGINEERED HUMAN ANTI-TNF-ALPHA ANTIBODY, CDP571, IN RA PATIENTS ARE SAFE AND EFFECTIVE/
Authors: RANKIN ECC CHOY EHS SOPWITH M VETTERLEIN O PANAYI GS ISENBERG DA
Citation: Ecc. Rankin et al., REPEATED DOSES OF 10 MG KG OF AN ENGINEERED HUMAN ANTI-TNF-ALPHA ANTIBODY, CDP571, IN RA PATIENTS ARE SAFE AND EFFECTIVE/, Arthritis and rheumatism, 38(9), 1995, pp. 197-197
THE EFFECT OF AN ENGINEERED HUMAN ANTITUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) ANTIBODY (AB) ON INTERLEUKIN-6 (IL-6) AND BONE MARKERS IN RHEUMATOID-ARTHRITIS (RA) PATIENTS
Authors: CHOY EHS KASSIMOS D KINGSLEY GH PANAYI GS RANKIN ECC ISENBERG DA VETTERLEIN O SOPWITH M EASTELL R
Citation: Ehs. Choy et al., THE EFFECT OF AN ENGINEERED HUMAN ANTITUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) ANTIBODY (AB) ON INTERLEUKIN-6 (IL-6) AND BONE MARKERS IN RHEUMATOID-ARTHRITIS (RA) PATIENTS, Arthritis and rheumatism, 38(9), 1995, pp. 198-198
SEROLOGICAL EFFECTS OF REPEATED DOSES OF AN ENGINEERED HUMAN ANTI-TNF-ALPHA - ANTIBODY, CDP571, IN PATIENTS WITH RHEUMATOID-ARTHRITIS (RA)
Authors: RANKIN ECC CHOY EHS EHRENSTEIN MR RAVIRAJAN CT SOPWITH M VETTERLEIN O PANAYI GS AISENBERG DA
Citation: Ecc. Rankin et al., SEROLOGICAL EFFECTS OF REPEATED DOSES OF AN ENGINEERED HUMAN ANTI-TNF-ALPHA - ANTIBODY, CDP571, IN PATIENTS WITH RHEUMATOID-ARTHRITIS (RA), Arthritis and rheumatism, 38(9), 1995, pp. 758-758
CLINICAL-EXPERIENCE WITH CDP571, AN ENGINEERED ANTI-TNF-ALPHA ANTIBODY
Authors: STEPHENS S EMTAGE S VETTERLEIN O ATHWAL D CHAPLIN L SOPWITH M BODMER M
Citation: S. Stephens et al., CLINICAL-EXPERIENCE WITH CDP571, AN ENGINEERED ANTI-TNF-ALPHA ANTIBODY, Journal of cellular biochemistry, 1994, pp. 216-216
Risultati: 1-14 |